Longevity.Technology argues peptide medicine must close the gray market
The commentary frames unregulated research-peptide supply as the central obstacle to legitimate peptide therapeutics gaining clinical footing.
TR
By Tom Reyes · Markets Editor
Oct 5 14:54 ETSource: Longevity.Technology
The wire
- 01An opinion piece in Longevity.Technology makes the case that the future of peptide medicine depends on displacing gray-market research-chemical supply with regulated products.
- 02Operators and prescribers tracking BPC-157, TB-500 and longevity peptides face the same sourcing and liability questions the piece raises.
- 03It is commentary rather than reporting, with no new regulatory action, data or enforcement attached.
From the source
Read at longevity.technologyThe future of peptide medicine is about closing the gray market
